Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Phipps added, to prevent the risk of contamination, the U.S
PMID 16368442
The bulk of the IPOs proceeds will help bankroll the companys planned Phase III trial for its lead obesity candidate MET-097i, an injectable, ultra-long-acting GLP-1 receptor agonist that is currently in Phase II trials
has received lecture fees from AstraZeneca and Novo Nordisk
The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE -/- and LDLr -/- mice by a mechanism that includes inflammatory pathways
doi:10.1016/j.molcel.2013.01.018 3
US$ 24.87
US$ 24.42
US$ 27.80
US$ 28.99
US$ 22.63
